FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / I- ! I		00540	
Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERS	HIP
---	-----

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
houre per reenonee.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* NOYES TIMOTHY P					2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]						(Che	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O AEF	`	irst) HERAPEUTICS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/29/2024							below)	(give title		er (specify ow) ICER	
930 WINTER STREET, SUITE M-500					4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	AM M	[A	02451									X Form filed by One Reporting Person Form filed by More than One Report Person				
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy											
	☐ the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				2. Transaction Date Month/Day/	Execution Date		Date	e, Transaction Disposed Code (Instr.		rities Acquired (A) or od Of (D) (Instr. 3, 4 are (A) or (D)		5. Amoun Securities Beneficia Owned Fo	s Form (D) or ollowing (I) (In	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	Indirect	
							Code V	Amount				nsaction(s) str. 3 and 4)				
			Table II - D (e					uired, Dis s, options				Owned				
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, Tr or Exercise (Month/Day/Year) if any Co		Code	nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	Owner Form: Direct or Ind (I) (Ins	(D) Beneficial Ownership rect (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	m(3)		
Stock Option (Right to Buy)	\$18.095	01/29/2024		A		200,000		(1)	01/28/2034	Common Stock	200,000	\$0	200,000	0 D		

Explanation of Responses:

1. The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 29, 2024.

/s/ George A. Eldridge, Attorney-in-Fact

** Signature of Reporting Person

01/31/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.